3f4d7ca5-e07b-4872-bc0b-226eafaf7dcd
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 76
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.450
- ALLOGRAFT_REJECTION+0.380
- INTERFERON_GAMMA_RESPONSE+0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.350
- INFLAMMATORY_RESPONSE+0.330
- IL6_JAK_STAT3_SIGNALING+0.310
- COMPLEMENT+0.290
- HEDGEHOG_SIGNALING+0.290
- MTORC1_SIGNALING+0.280
- GLYCOLYSIS+0.270
Top 10 suppressed
- MYC_TARGETS_V2-0.450
- MITOTIC_SPINDLE-0.270
- P53_PATHWAY-0.160
- TNFA_SIGNALING_VIA_NFKB-0.140
- MYOGENESIS-0.100
- UV_RESPONSE_DN-0.050
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.040
- HYPOXIA-0.040
- ESTROGEN_RESPONSE_EARLY-0.030
- APICAL_JUNCTION-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM5359441 | — | — | 0.773 |
| 2 | 79cf2255-57c7-4f54-8f0b-1e0f4a8cc8b5 | — | — | 0.730 |
| 3 | TCGA-39-5022-01A-21R-1820-07 | — | cohortSQ1 | 0.728 |
| 4 | SRR1313165 | — | E | 0.726 |
| 5 | s0094235 | — | — | 0.720 |
| 6 | DRR168598 | — | — | 0.717 |
| 7 | TCGA-D8-A1JK-01A-11R-A13Q-07 | — | C | 0.717 |
| 8 | ff02e85e-2f87-4832-aaea-3322db33c57a | — | — | 0.710 |
| 9 | SAMN03290924 | — | — | 0.700 |
| 10 | SAMN03290917 | — | — | 0.696 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.380 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |